Scholarlink

Background <p>Oral submucous fibrosis (OSMF) is a chronic, progressive, potentiallymalignant disorder. Intralesional triamcinolone acetonide (TA) + hyaluronidase (HA)remains widely used, yet its functional effectiveness in real-world settings is uncertain.</p> Methods <p>A retrospective cohort (<i>n</i> = 54; Stage II–III) received six biweekly TA 20 mg +HA 750 IU injections plus adjuncts continued for six months. Outcomes: change inmaximum inter-incisal opening (MIO), pain (VAS), quality of life (OHIP-14), andhaemoglobin. Linear regression tested predictors (baseline MIO, stage, anaemia,compliance).</p> Results <p>Mean MIO 22.4–24.6 mm (Δ 2.2 mm; <i>p</i> = 0.08; d = 0.49); 11% achieved ≥ 5mm gain. VAS decreased by 1 point (<i>p</i> = 0.04); OHIP-14 unchanged (<i>p</i> = 0.13).Regression R<sup>²</sup> = 0.07 (adjusted R<sup>²</sup> = 0.03; F(4,49) = 0.92, <i>p</i> = 0.46). No adverse events;compliance 65%.</p> Conclusion <p>Intralesional TA + HA yielded limited functional improvement and modestsymptom relief. Multimodal, preventive, and regenerative approaches requireprospective validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Marginal Impact of Intralesional Regimens in Oral Submucous Fibrosis: A Tertiary-Centre Retrospective Study

  • 期刊论文

  • 发表日期：

    2026年1月7日

查看全文
  • Chandrashekhar Chattopadhyay,
  • Vikas Deo,
  • Charu Chouhan,
  • Mamta Patel,
  • Ayush Garg,
  • Priti Airun

摘要

Background

Oral submucous fibrosis (OSMF) is a chronic, progressive, potentiallymalignant disorder. Intralesional triamcinolone acetonide (TA) + hyaluronidase (HA)remains widely used, yet its functional effectiveness in real-world settings is uncertain.

Methods

A retrospective cohort (n = 54; Stage II–III) received six biweekly TA 20 mg +HA 750 IU injections plus adjuncts continued for six months. Outcomes: change inmaximum inter-incisal opening (MIO), pain (VAS), quality of life (OHIP-14), andhaemoglobin. Linear regression tested predictors (baseline MIO, stage, anaemia,compliance).

Results

Mean MIO 22.4–24.6 mm (Δ 2.2 mm; p = 0.08; d = 0.49); 11% achieved ≥ 5mm gain. VAS decreased by 1 point (p = 0.04); OHIP-14 unchanged (p = 0.13).Regression R² = 0.07 (adjusted R² = 0.03; F(4,49) = 0.92, p = 0.46). No adverse events;compliance 65%.

Conclusion

Intralesional TA + HA yielded limited functional improvement and modestsymptom relief. Multimodal, preventive, and regenerative approaches requireprospective validation.